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recovery upon overt diabetesLena Oppenländer 1,2,6,12, Subarna Palit 4,9,12, Kerstin Stemmer 3,6,10, Tobias Greisle 1,2,6, Michael Sterr 1,6,
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Fabian J. Theis 4,8,9,***, Heiko Lickert 1,2,6,7,*ABSTRACT
Objective: The effectiveness of bariatric surgery in restoring b-cell function has been described in type-2 diabetes (T2D) patients and animal
models for years, whereas the mechanistic underpinnings are largely unknown. The possibility of vertical sleeve gastrectomy (VSG) to rescue far-
progressed, clinically-relevant T2D and to promote b-cell recovery has not been investigated on a single-cell level. Nevertheless, characterization
of the heterogeneity and functional states of b-cells after VSG is a fundamental step to understand mechanisms of glycaemic recovery and to
ultimately develop alternative, less-invasive therapies.
Methods: We performed VSG in late-stage diabetic db/db mice and analyzed the islet transcriptome using single-cell RNA sequencing (scRNA-
seq). Immunohistochemical analyses and quantification of b-cell area and proliferation complement our findings from scRNA-seq.
Results: We report that VSG was superior to calorie restriction in late-stage T2D and rapidly restored normoglycaemia in morbidly obese and
overt diabetic db/db mice. Single-cell profiling of islets of Langerhans showed that VSG induced distinct, intrinsic changes in the b-cell tran-
scriptome, but not in that of a-, d-, and PP-cells. VSG triggered fast b-cell redifferentiation and functional improvement within only two weeks of
intervention, which is not seen upon calorie restriction. Furthermore, VSG expanded b-cell area by means of redifferentiation and by creating a
proliferation competent b-cell state.
Conclusion: Collectively, our study reveals the superiority of VSG in the remission of far-progressed T2D and presents paths of b-cell
regeneration and molecular pathways underlying the glycaemic benefits of VSG.
 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sequencing1. INTRODUCTION
Pancreatic b-cells secrete insulin with precision to regulate glucose
uptake by peripheral tissues and maintain normoglycaemia. Obesity-
linked T2D is characterized by a condition of insulin resistance and
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insulin resistance [1,2]. Reportedly, functional loss of b-cell mass
seems to be a consequence of glucolipotoxicity and oxidative, in-
flammatory and ER stress [3]. Among different mechanisms proposed
for b-cell failure, b-cell dedifferentiation has been identified as a
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Original Articleprocess, b-cells lose their identity and acquire a characteristic
signature distinct from functional b-cells that includes the induction of
Aldehyde-dehydrogenase 1 A3 (Aldh1a3) [4e8]. The exact causes of
the loss of b-cell identity are not fully understood and remain an active
and promising area of investigation, especially with respect to
exploring therapeutic interventions aimed at inducing b-cell rediffer-
entiation to a functional state. In fact, there are reports showing that
the dedifferentiated state of b-cells can be partly reversed by strict
dietary intervention [9,10] and combined insulin and glucagon-like
peptide-1 (GLP-1)/estrogen conjugate-mediated targeted delivery to
b-cells [11]. Redifferentiation, however, cannot be accomplished by
common glucose-lowering agents [10]. Classic insulin substitutive
therapies may involve adverse complications, including life-threatening
hypoglycaemia, and are often insufficient for controlling glycaemia in
advanced stages of T2D, whereas alternative glucose-regulating
pharmacotherapies are currently limited to a few anti-diabetic phar-
maceuticals of varying effect [12e14]. Bariatric surgery has risen in
reputation for its lasting weight-lowering effects in severely obese
patients as well as achieving high T2D remission rates [15e17].
Though it was initially attributed to solely calorie-restrictive mecha-
nisms, it has become clear during the last decade that the profound
benefits of bariatric surgery can most likely be explained by the
combined actions of a multitude of physiological adaptations [18,19].
Strikingly, studies of human and animal models show that glycaemic
control is rapidly improved after bariatric surgery and prior to its pri-
mary effect on weight loss [20e24], suggesting that factors inde-
pendent of decreased obesity cause changes in glucose regulation and
diabetes remission. VSG is the most commonly performed bariatric
surgical procedure [25] and exerts remarkable metabolic effects,
including islet intrinsic effects and improved peripheral insulin sensi-
tivity [21]. VSG has recently been shown to enhance b-cell function
independent of body weight, paralleled by marked intrinsic adaptations
in the islet transcriptome in pre-diabetic high fat diet (HFD)-fed mice
[20], and improve b-cell diabetes markers in early diabetic (8- to 10-
week-old and 4-week-old) db/db mice [21,26]. The exact molecular
complement of T2D after VSG is not yet fully resolved. Current literature
has mainly focused on models resembling early insulin-compensatory
stages of T2D, such as diet-induced obesity (DIO) models and young
db/db mice. However, studies investigating the glucoregulatory
mechanisms of VSG in models mirroring clinical features of extreme
obesity and severe T2D are still missing. Db/db mice have an inbuilt
adaptive flexibility that enables them to adjust insulin production rates
and b-cell mass relative to the metabolic demand in early stages
[27,28] while showing progressive b-cell failure and dedifferentiation
[10,29] and a decline in proliferative capacity and b-cell mass after 12
weeks of age [28]. Here, we employed 16- to 18-week-old db/db mice
that mirror clinical features of obesity-linked T2D [30] to investigate
whether VSG is able to reverse far-progressed T2D. Unlike in previous
studies, we took advantage of single-cell transcriptomics to investigate
1) how VSG induces b-celleintrinsic glucoregulatory mechanisms for
diabetes remission, 2) whether VSG affects heterogeneous b-cell
states and 3) whether VSG supports b-cell redifferentiation to a
functional glucose-sensing state.
2. RESULTS
2.1. VSG restores glycaemia and improves b-cell function in
overtly diabetic db/db mice
Preoperatively, db/db mice presented a strong obese-diabetic
phenotype with insulin resistance. Mice achieved an average body
weight (BW) of 51.7 g and fasting glycaemia of 540 mg/dL while2 MOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. Tlacking a regulated insulin response during a mixed-meal tolerance
test (MMTT, Figure S1). Mice of this cohort were homogeneously
allocated to VSG and sham surgery groups. An additional sham-
operated, pair-fed (PF) group was calorically restricted to match the
postoperative food intake of the VSG group (Figure 1A). Previous
studies showed that VSG both improved glucoregulation in pre-
diabetes HFD models [20,23] and reversed glycaemia in early-onset
T2-diabetic db/db mice [21], while PF accomplished the former but
only partly succeeded in the latter. However, the effectiveness of VSG
in overt T2D mice, in which regenerative capacity declines, remains to
be addressed. To test the effects of VSG in 18- to 20-week-old db/db
mice on glucose regulation dependently of gastrointestinal functions,
VSG and control mice underwent an MMTT. Despite similar weight
profiles and food intake in all groups, arising from genetically-driven
hyperphagia in db/db mice, glycaemic control markedly improved
from VSG within just two weeks of intervention (Figure 1B, Figure S1).
These findings indicate that VSG is capable of rapidly reversing long-
term T2D independently of body weight in aged db/db mice, similar to
reports in early T2-diabetic (8- to 10-week-old) db/db mice [21]. We
show that VSG rescued fasting glycaemia almost to the levels of WT
mice, increased fasting insulin levels, and improved glycaemia during
an MMTT in comparison to Sham and PF (Figure 1CeE). VSG mice
secreted 3-fold more insulin upon oral application of a liquid diet than
Sham and PF (Figure 1F). This suggests that VSG is most likely able to
restore glycaemic control by increasing basal and postprandial insulin
secretion. Interestingly, unlike in pre-diabetes models, PF glucose and
insulin levels did not differ from Sham, suggesting that a solely calorie
restrictionebased intervention is no longer sufficient to restore gly-
caemic control after prolonged and severe T2D.
2.2. Islets of extreme obese-diabetic mice show massive b-cell
dedifferentiation
While the metabolic phenotype of the db/db mouse is well described
[28], there are no reports on how islets and b-cells respond to sus-
tained T2D. To this end, we used single-cell RNA sequencing (scRNA-
seq) to analyze the islet transcriptomes of 18- to 20-week-old wild-
type (WT) (n ¼ 2) and sham-operated db/db mice (n ¼ 2)
(Figure 2A). Sham mice had developed a severe state of obesity
(Figure 2B) and showed markedly enhanced levels of fasting blood
glucose (Figure 2C) and fasting insulin (Figure 2D), permitting the
investigation of the underlying molecular mechanisms of islet and b-
cell dysfunction in an overt T2D model.
In order to generate a highly resolved profile of pancreatic islets upon
overt diabetes, we analyzed 19,878 endocrine cells (expressing
Chromogranin A, Chga) using scRNA-seq (WT: n¼ 2, 10,725 cells; db/
db: n ¼ 2, 9153 cells). Single cells were clustered and visualized
based on their transcriptomic similarity using an unbiased graph-
based approach. Specifically, we used Uniform Manifold Approxima-
tion and Projection [31] (UMAP) and Louvain clustering [32] to assign
cells into five main endocrine populations: a-cells, b-cells, d-cells,
pancreatic polypeptide (PP) cells and polyhormonal cells. Clusters were
manually annotated based on the predominant expression of specific
marker genes, namely, glucagon (Gcg), insulin (Ins1), somatostatin
(Sst) and pancreatic polypeptide (Ppy) or a combination of hormones
that defined polyhormonal cells. Our scRNA-seq data revealed an
altered cell composition in diabetic islets as well as intrinsic changes in
the gene expression profiles of endocrine clusters (specifically b-cells),
indicated by a shift in cell cluster location in the UMAP space. Indeed,
the Sham mice showed a proportional decline in the percentage of b-
cells, from 74.65% in WT to 55.86%, while a-, d-, PP- and poly-
hormonal cells increased compared to WT (Figure 2E). Differential genehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: VSG restores glycaemia and improves b-cell function in overtly diabetic db/db mice. A, Schematic of single-cell experiment. 16- to 18-week-old db/db mice were
subjected to VSG, sham surgery (Sham) and sham surgery with subsequent pair-feeding. Animals were challenged with a mixed-meal tolerance test (MMTT) two weeks prior to
surgery and one day before the end of experiment at day 14, followed by islet scRNA-seq (age 18e20 weeks). B, Postsurgical changes in BW (WT, n ¼ 8; Sham, n ¼ 6, PF, n ¼ 6;
VSG, n ¼ 4; two-way ANOVA with Bonferroni’s post hoc test; differences in VSG versus Sham and VSG versus PF were not statistically significant; VSG versus WT (d4, p ¼ 0.099;
d5, p ¼ 0.0045; d6-d14, p < 0.0001)). C, Fasting blood glucose (WT, n ¼ 7; Sham, n ¼ 7, PF, n ¼ 5; VSG, n ¼ 4; one-way ANOVA with Bonferroni’s post hoc test; WT versus
Sham (p < 0.0001), WT versus PF (p < 0.0001), Sham versus VSG (p < 0.0001), PF versus VSG (p ¼ 0.0003)) and D, fasting insulin levels (WT, n ¼ 8; Sham, n ¼ 6; PF, n ¼ 4;
VSG, n ¼ 4; one-way ANOVA with Bonferroni’s post hoc test; WT versus VSG (p < 0.0001), Sham versus VSG (p ¼ 0.0008), PF versus VSG (p ¼ 0.0047)). E, Area under the curve
(AUC) of blood glucose levels during an MMTT (WT, n ¼ 7; Sham, n ¼ 7, PF, n ¼ 5; VSG, n ¼ 4; one-way ANOVA with Bonferroni’s post hoc test; Sham versus VSG (p < 0.0001);
PF versus VSG (p ¼ 0.0011) F, AUC of insulin levels during an MMTT (WT, n ¼ 8; Sham, n ¼ 7, PF, n ¼ 5; VSG, n ¼ 4; one-way ANOVA with Bonferroni’s post hoc test; Sham
versus VSG (p ¼ 0.0002); PF versus VSG (p ¼ 0.0016). All data are presented as mean  s.e.m.expression analysis in b-, a-, d-, and PP-cells revealed that Sham-
derived b-cells were transcriptionally more strongly modulated than
a-, d-, and PP-cells in the db/db model (Figure S2, Supplementary
Table 5). This suggests that b-cells are more sensitive to the hostile
metabolic environment than other islet cell types. Of note, Sham-
derived a-cells exclusively co-expressed Ppy but showed fewer
differentially-expressed genes, including adaptive response genes
[33e36] (Figure S2). Gene Ontology (GO) analysis revealed an upre-
gulation of the translation machinery and downregulation of cellular
respiration in Sham-derived diabetic a-cells (Figure S2). Because of
these findings, we next sought to transcriptionally characterize the
identity and functionality of b-cells. Interestingly, Sham-derived b-
cells showed reduced expression levels of b-cell identity (Insulin-1,
Ins1; transcription factor Mafa [37], Mafa; Pancreatic and duodenal
homeobox 1, Pdx1; Urocortin 3 [38], Ucn3; Neuronal differentiation 1
[39], Neurod1) and b-cell functional markers (Solute carrier family 2,
Slc2a2, also known as Glut2; Transient receptor potential cation
channel subfamily M member 5, Trpm5; Proprotein convertase 1,
Pcsk1; Figure 2FeH and L). b-cell failure in T2D is characterized by
gradual loss of identity and function, which involves b-cell dediffer-
entiation in both rodents [4,40] and humans [7]. Aldh1a3 is the most
prominent and established marker of b-cell dedifferentiation during b-
cell failure [40], found to be robustly increased in the majority of db/db
Sham-derived b-cells. Other markers of b-cell dedifferentiation,
including Gastrin [41,42] (Gast), Vitamin D binding protein [43] (Gc) and
Cluster of differentiation 8144 (Cd81), Collectrin [11] (Cltrn) andMOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comGlutathione peroxidase 3 [11] (Gpx3) were similarly increased in db/db
b-cells (Figure 2I-L). The changes observed in our scRNA-seq data
were further corroborated by immunohistochemistry (Figure 2MeP).
Consequently, our data imply a transcriptional reprogramming of b-
cells during disease progression in db/db mice involving the loss of
identity and key functional markers and a progressive increase in
characteristic b-cell dedifferentiation markers. Collectively, we un-
derscore the prominence of the db/db mouse to better understand the
process of b-cell failure and thereby provide an opportunity to examine
b-cell protective and regenerative mechanisms through therapeutic
interventions.
2.3. VSG distinctly improves b-cell identity and function
In order to gain insights into the b-cell mechanisms governing the
fast recovery of glycaemia by VSG, we analyzed the single-cell
transcriptomes of Sham, PF controls and VSG islets. Prior studies
have either focused on pre-diabetes models and used bulk islet
transcriptomics [20] or early stage T2D models [21,26] addressing
selected b-cell markers. However, the impact of VSG on islets has
not been dealt with at a single-cell resolution to address cell type and
cell stateespecific gene expression profiles after VSG. To fill this
knowledge gap, we profiled 35,941 single pancreatic endocrine cells
from Sham, PF and VSG groups (Sham: n¼ 2, 9153 cells; PF: n¼ 1,
13,184 cells; VSG: n ¼ 2, 13,604 cells) 14 days post-surgery, which
formed five major clusters corresponding to distinct cell-types (a-
cells, b-cells, d-cells, PP-cells and polyhormonal cells) based onccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
Figure 2: Islets of extreme obese-diabetic mice reveal massive b-cell dedifferentiation. A, Experimental design of islet scRNA-seq of wildtype and 18- to 20-week-old Sham
db/db mice. B, Sham mice showing markedly enhanced body weight (WT, n ¼ 8; Sham, n ¼ 7; p < 0.0001) C, fasting insulin (WT, n ¼ 8; Sham, n ¼ 6; p ¼ 0.0002) and D,
fasting blood glucose levels (WT, n ¼ 7; Sham, n ¼ 7; p < 0.0001). Data was analyzed by unpaired student’s t-tests. E, UMAP plot of 19,878 endocrine cells from WT and Sham
mice. Colours indicate the five main endocrine cell types, and colour tone differentiates between WT (darker tones) and Sham (lighter tones). Numbers highlight the proportion of
each cell cluster in WT or Sham, respectively. FeK, Violin plots indicating gene expression of selected b-cell maturity (Ins1, Mafa, Slc2a2) and dedifferentiation (Aldh1a3, Gast, Gc)
markers, highlighting key differences between WT and Sham b-cells. Violin plots show the distribution of expression as a kernel density estimate (kde) fit. Points within the violin
indicate individual cell points. L, Changes in gene expression of major markers of b-cell identity, function, dedifferentiation and immaturity along a diffusion trajectory path from WT
to Sham. Cells are ordered using a random-walkebased distance metric computed using diffusion pseudotime (DPT). A starting point or root cell is randomly selected within the
WT b-cells and cell transition from the origin is studied thereafter. Expression shown is the running average along the inferred trajectory, scaled to the maximum observed level per
gene. Smaller clusters were removed to ensure smooth transition. MeP, Immunohistochemical analysis of Slc2a2, MafA, UCN3, Insulin and Aldh1a3 in b-cells of WT and Sham
mice at study end. Scale is 50 mm. All data are presented as mean  s.e.m.
Original Articlecanonical marker expression (Figure 3A). b-cells revealed a large
number of differentially regulated genes, while a-, d- and PP-cells
showed fewer transcriptional differences after VSG when
compared to Sham, with only a small portion of genes showing4 MOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. Tdifferential expression (Figure S3, Supplementary Table 5). However,
it should be noted here that scRNA-seq is less sensitive in capturing
differences in small cell clusters, such as a-, d- or PP-cells.
Collectively, our data not only captures the fact that b-cells arehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: VSG distinctly improves the identity and function of b-cells. A,B, UMAP plots of 35,941 endocrine cells from Sham, VSG and PF. Colours in (a) indicate the five main
endocrine cell clusters and in (b) distinguish b-cells specifically according to the three groups. C, Abstracted graph of cluster connectivity assessing transcriptomic similarity
between VSG-, PF-, Sham- and WT-derived b-cells, inferred using PAGA. PAGA is based on a statistical method that measures relatedness between single-cell clusters, with edge
weights indicating link significance. D,E, Gene expression for key genes involved in b-cell identity and function changed upon VSG. (d) Dot plot showing that VSG-derived b-cells
upregulated essential maturity markers and downregulated dedifferentiation markers. (e) Dot plot showing genes critical for b-cell function and metabolism, insulin processing and
exocytosis. Color intensity shows normalized mean expression in a group; dot size indicates the percentage of cells that express the corresponding gene. Expression is scaled per
gene. FeJ, Immunohistochemical analysis of MafA, Slc2a2, Insulin, Aldh1a3, Slc5a10 and Pcsk1 in b-cells of WT, Sham, PF and VSG mice at study end. Scale is 50 mm K,
Volcano plots indicating differences in the number of genes that were differentially expressed when comparing b-cells from Sham and VSG versus b-cells from Sham and PF,
obtained from differential analysis testing using limma-trend. Red dots denote significantly regulated genes thresholded on significance levels (absolute estimated log (fold change
(FC))>0.15 and B > 150). p-values were corrected for multiple testing using BH. L, Heatmap showing expression changes in genes that were differentially regulated across Sham,
VSG and WT b-cells. As a first step, a trajectory of b-cell dedifferentiation upon treatment was estimated using diffusion pseudotime (DPT) and randomly assigning a root cell within
the dedifferentiated cells. b-cells were further grouped according to Sham, VSG and WT and gene expression trends were visualized along this one-dimensional axis. Y-axis shows
normalised gene expression as the running average along the inferred trajectory, scaled to the maximum observed level per gene. M, Enrichment analysis of GO terms and KEGG
pathways of upregulated genes at estimated log (FC) > 0.15 and B > 150 in b-cells between VSG and PF. Method limma-trend was used to identify differentially expressed genes
and gene-set enrichment was done with EnrichR webtool using Fisher’s exact test to find enriched terms and pathways. X-axis indicates elog10 (adjusted p-value).
MOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original Articlemostly affected in T2D (Figure 2), but also that b-cells are modulated
by VSG intervention and may likely play a crucial role in the islet
intrinsic glucoregulatory mechanisms of VSG. In order to unravel
specific mRNA changes underlying VSG-mediated glycaemic re-
covery, we then compared the b-cell transcriptome of VSG with that
of diabetic Sham and PF controls. b-cells from the VSG group
clustered separately from those of Sham and PF groups in the UMAP
space, emphasizing that VSG invokes distinct transcriptional
changes that may underlie the recovery of b-cells. The PF b-cells
clustered more closely with Sham b-cells, suggesting shared tran-
scriptional programs and divergent effects of PF and VSG on the b-
cell transcriptome (Figure 3B). These observations were further
supported by Partition-based graph abstraction (PAGA) analysis,
which is based on a statistical framework that measures the con-
nectivity and relatedness of single-cell clusters [45]. The nodes of
the abstracted graph represent b-cell clusters from the four distinct
groups, with the edges implicating the expected trajectory. PAGA
analysis highlighted a strong connectivity between Sham- and PF-
derived b-cells and a weaker connectivity between VSG and
Sham- or PF-derived b-cells (Figure 3C). These findings suggest that
VSG induces a distinct b-cell signature compared to Sham and PF
controls, while PF intervention does not induce great alterations in
the b-cell transcriptome. Consequently, we charted expression
profiles of key b-cell identity and function markers and found that
VSG rapidly improved the expression of b-cell transcription factors
and maturation markers (Ins1, Mafa, Pdx1, Isl1, Nkx2-2, Pax6, Foxo1
and Neurod1) within only two weeks of intervention. Ucn3 (matu-
ration marker) expression was unaffected by VSG, suggesting that
long-term intervention may be required. Concomitantly, the VSG-
derived b-cells had a significantly decreased expression of dedif-
ferentiation markers Aldh1a3, Cd81, Retinol binding protein 4 [46]
(Rbp4), Sodium/glucose cotransporter 5 [11] (Slc5a10), Gast, Gc and
Cholecystokinin [11] (Cck, Figure 3D). Immunohistochemical stain-
ings corroborated that the transcriptional effects observed after VSG
majorly translated to protein levels (Figure 3F, H and I). Genes
identified as playing a crucial role in glucose sensing, such as
Glucokinase (Gck), Trpm5, Calcium voltage gated channel subunit
alpha 1 A (Cacna1a) and Free fatty acid receptor 1 (Ffar1), were
robustly increased in VSG (Figure 3E). The major glucose sensor in
b-cells, Slc2a2, was found to be partly restored by VSG (shown by
immunofluorescence) but was surprisingly not mirrored at the
mRNA-level (Figure 3G), potentially owing to dietary regulation of
Slc2a2 protein levels [47,48]. The critical gene for proinsulin pro-
cessing Pcsk1 was upregulated at both the mRNA and protein
expression levels (Figure 3E and J). Additional insulin processing
genes, such as Proprotein convertase 2 (Pcsk2) and Carboxypepti-
dase E (Cpe), were also expressed at higher levels in VSG. Genes
involved in insulin secretion, such as Chromogranin B [49] (Chgb),
Synaptotagmin 7 [50] (Syt7) and Synaptosomal-associated protein
25 kDa [51] (Snap25), were significantly upregulated in VSG
(Figure 3E). To assess gene expression changes with regard to WT, a
selection of genes from all groups is shown as violin plots (Figure
S3). In line with the lack of metabolic effects of PF, the b-cell
signature was only mildly altered. PF did not greatly impact b-cell
identity, dedifferentiation and functionality markers (Figure 3D and E)
and enrichment of upregulated genes in PF compared to Sham, and
VSG solely revealed terms related to ribosomal and mitochondrial
functions (Figure S3).
To further examine the extent to which VSG was able to improve b-cell
identity and function, b-cells were first ordered along a trajectory using
diffusion pseudotime [52] (DPT), followed by grouping according to6 MOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. TSham, VSG and WT and reconstructing expression changes along
PAGA paths for a given set of genes (Supplementary Table 1 and
Methods). VSG ameliorated the expression of several prominent
identity and functional markers and simultaneously decreased the
expression of genes involved in dedifferentiation. A multitude of
markers, including Ins1, Mafa, Neurod1, Cck, Gast, Cltrn, Aldh1a3, Gc
and Cd81, displayed a gene expression pattern trending towards WT
levels (Figure 3L, Supplementary Table 1). This observation is in line
with the previous PAGA analysis and shows that VSG, but not PF,
inched towards a WT b-cellelike identity. To understand the unique
signaling and functional pathways altered by VSG, we analyzed the
VSG b-cell transcriptome through GO and the Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway enrichment analyses of signifi-
cantly upregulated genes. Interestingly, differential gene expression
analysis revealed a larger set of genes being significantly regulated in
the VSG group compared to Sham and PF. Furthermore, a high tran-
scriptional similarity was again observed between PF- and Sham-
derived b-cells, supporting a discrete b-cell phenotype in the VSG
group (Figure 3K). We identified pathways associated with the unfolded
protein response (UPR), endoplasmic reticulum protein processing and
insulin secretion to be upregulated in VSG versus PF, suggesting that
VSG enhances insulin synthesis and pathways that ensure proper
folding of insulin (Figure 3M). In summary, our findings reveal that VSG,
but not PF, induces significant changes in the b-cell transcriptome
shortly after surgery that likely mirror the glycaemic correction and
recovery of b-cell function after VSG.
2.4. VSG augments UPR and enhances ERAD to counteract ER
stress
The UPR is a critical adaptive response to endoplasmic reticulum
stress (ER stress), restoring cell homeostasis and, when exceeding
manageable levels, contributing to loss of b-cell mass in T1D and
T2D [53,54]. We scored canonical UPR genes (Supplementary
Table 2 and Methods) in b-cells and observed that VSG signifi-
cantly increased the overall expression score compared to WT, Sham
and PF (Figure 4A). Heat shock protein family A member 5 (Hspa5,
also known as 78-kDa glucose-regulated protein, GRP78), a major ER
chaperone and upstream regulator of the UPR with anti-apoptotic
properties [55], was found upregulated on the mRNA level upon
VSG. Additionally, VSG increased the expression of numerous other
UPR genes, such as X-box binding protein 1 (Xbp1), Wolfram syn-
drome 1 (Wfs1), Activating transcription factor 6 (Atf6) and Eukaryotic
translation initiation factor 2 alpha kinase 3 (Eif2ak3, also known as
Perk, Figure 4B), which play a role in b-cell homeostasis [56,57],
adaptive b-cell proliferation [58] and insulin processing [59]. ER-
associated protein degradation (ERAD) serves to mitigate ER stress
and has recently also been attributed an indispensable role in the
maintenance of b-cell identity and function [60,61]. Our data reveal
that VSG specifically increased the score of characteristic ERAD
markers in b-cells (Supplementary Table 2 and Methods) (Figure 4C).
In particular, the expression of the major components of the ERAD
complex, SEl1L adaptor subunit of ERAD E3 ubiquitin ligase (Sel1l)
and Synoviolin 1 [62] (Syvn1, also known as Hrd1), were increased
upon VSG (Figure 4D). Additionally, we found the expression of other
ERAD-related genes, such as DnaJ Heat Shock Protein Family
(Hsp40) Member B2 (Dnajb2), Dnajb4, ER lipid raft associated 1
(Erlin1), Homocysteine-responsive endoplasmic reticulumeresident
ubiquitin-like domain member 1 protein (Herpud1) and Osteosar-
coma amplified 9 (Os9) increased in the b-cells of VSG-treated mice
(Figure 4D). Collectively, our results reveal that VSG enhances
adaptive-response mechanisms to ER stress in b-cells, which likelyhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: VSG augments UPR and enhances ERAD to counteract ER stress. A, Box plots showing the distribution of UPR scores per group, calculated using characteristic UPR
markers. Box plots show median (WT ¼ 0.489, Sham ¼ 0.437, PF ¼ 0.376, VSG ¼ 0.508), quartile and whisker values. Points within the box plot indicate individual data points or
cells in that corresponding group. VSG showed an increased UPR score compared to WT (p < 0.0001), Sham (p < 0.0001) and PF (p < 0.0001) using Welch’s Test (one way) with
Bonferroni’s post-hoc test. B, Matrix plot showing expression of selected genes involved in the three main signalling branches of the UPR. Color gradient indicates mean z-score
scaled gene expression. C, Box plots showing the distribution of ERAD scores per group, calculated using canonical ERAD genes. Box plots show median (WT ¼ 0.398,
Sham ¼ 0.497, PF ¼ 0.461, VSG ¼ 0.519), quartile and whisker values. Points within the box plot indicate individual data points or cells in that corresponding group. VSG showed
a higher ERAD score compared to WT (p < 0.0001), Sham (p < 0.0001) and PF (p < 0.0001) using Welch’s Test (one way) with Bonferroni’s post-hoc test. D, Matrix plot showing
expression of selected genes involved in ERAD. Color gradient indicates mean z-score scaled gene expression.parallels the extreme insulin secretion upon VSG and indicates a VSG-
specific protective role of ERAD during ER stress in b-cells.
2.5. VSG shifts b-cells towards mature and extreme-like states
b-cell heterogeneity has now been well described in healthy and
diabetic conditions as well as during the process of de- and rediffer-
entiation [11,63e71]. However, it has not yet been established how
VSG affects b-cell subpopulations in terms of cell composition and
cell-specific marker expression. In order to catalogue heterogeneity of
b-cell states after VSG, we performed refined clustering on 28,230 b-
cells from WT (n ¼ 2), Sham (n ¼ 2), PF (n ¼ 1) and VSG (n ¼ 2).
Markers were shown separately for WT- and db/db-derived b-cells
(Sham, PF, VSG), as their expression profiles varied significantly. We
identified four major b-cell subpopulations and classified them as
mature, immature, dedifferentiated and extreme-like (Figure 5A). The
mature b-cell subpopulation exhibited the highest expression of b-cell
maturation markers and transcription factors (Mafa, Pdx1, Neurod1
and Nkx6-1) as well as functional markers (Ins1, Forkhead box protein
O1 (Foxo1) and Trpm5) in all groups (Figure 5B). With the purpose of
delineating group-specific proportional shifts in the subpopulations, we
estimated the relative fractional change in cell numbers. As antici-
pated, Sham and PF mice depicted a reduced fraction of mature b-MOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. This is an open a
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increased the fraction of mature b-cells (37%, Figure 5C). We next
performed differential expression testing within mature and dediffer-
entiated b-cells in order to investigate the cluster-specific transcrip-
tional changes arising upon VSG intervention. Interestingly, we found
that the VSG-derived mature b-cells had significantly higher levels of
b-cell functionality genes (Pcsk1, Pcsk2, Cpe and Chgb) compared to
mature b-cells of Sham, implying that VSG is able to boost the function
of mature b-cells (Figure S4, Supplementary Table 5). The molecular
identity of immature b-cells is increasingly being investigated.
Recently, a scRNA-seq study characterized an immature b-cell subset
based on low expression levels of Mafa and high expression levels of
Cltrn and Gpx3 [11]. Another study by our laboratory has recently
identified CD81 as a marker for immature and dedifferentiated b-cells
[44]. In our scRNA-seq dataset, only the WT b-cells presented a clearly
distinguishable immature subset (2%) with high expression levels of
Cltrn, Gpx3 and Cd81 and low expression of Mafa (Figure 5A and B,
Figure S4). In db/db b-cells, immature b-cells could not be distin-
guished from dedifferentiated b-cells (Figure S4), which highly
expressed Aldh1a3 and Cd81 and comprised the majority of the b-
cells (Figure 5AeC). The highest proportions of dedifferentiated b-cells
were present in Sham and PF (74% and 80% respectively), while levelsccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 7
Figure 5: VSG shiftsb-cells towardsmature and extreme-like states.A, UMAP plot showing refined clustering of 7183b-cells fromWT and 21,047b-cells from db/db (VSGþ PFþ Sham)
into four mainb-cell subpopulations. Colours indicate the subpopulations identified: mature, immature, dedifferentiated and extreme-likeb-cells, as well as control and intervention groups. B, Dot
plot showing expression changes of key genes involved in b-cell maturity, immaturity, dedifferentiation and extreme b-cell identity in WT b-cell subclusters (top panel) and db/db
(VSGþ PFþ Sham) b-cell subclusters (bottom panel). Color intensity shows normalized mean expression in a cell cluster; dot size indicates the percentage of cells in a cluster that express the
corresponding gene. Expression is scaled per gene. C, Proportion of cells per b-cell subpopulation inWT, Sham, PF and VSG.D, RNA velocity estimates of cell transitions applied to Sham and VSG
b-cells and direction of cell movement indicated as streamlines projected onto UMAP embedding (top panel). UMAP plots showing expression of key genes (Mafa, Aldh1a3, Cck) to delineate
dedifferentiation from mature cells.
Original Articlewere decreased in VSG (57%, Figure 5C). Dedifferentiated b-cells were
not present in WT. Yet displaying a dedifferentiated signature, VSG
improved the transcriptome of dedifferentiated b-cells. Markers of b-
cell dedifferentiation (Aldh1a3, Gast, Cck and Rbp4) were reduced
while b-cell identity and functionality markers (Ins1, Neurod1, Cpe,
Pcsk1, Pcsk2, Adrenoreceptor alpha A [72] (Adra2a), Claudin 4 [73]
(Cldn4) and Chgb) were increased in VSG compared to Sham (Figure
S4, Supplementary Table 5). In order to investigate the dynamics of8 MOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. Tmature and dedifferentiated b-cells, we performed an RNA velocity
analysis that included VSG and Sham groups [74]. We observed clear
transitions from mature b-cells towards a dedifferentiated state in
Sham, whereas VSG-derived dedifferentiated b-cells were distinctively
directed towards maturity (Figure 5D). These observations of cell
movements are indicative of dedifferentiation processes occurring in
Sham and promotion of redifferentiation processes by VSG. Further-
more, we computed velocity length and confidence in order to gainhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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insights about the rate of differentiation and coherence of the velocity
field, respectively, for each individual cell. Dedifferentiated b-cells
from VSG depicted a substantially faster pace of transition as well as
higher measure of confidence in RNA velocity compared to Sham,
suggesting more active cell profile changes after VSG (Figure S4;
Supplementary Table 3). Taken together, our findings 1) indicate that
VSG improves function in both mature and dedifferentiated b-cells and
2) reveal a role of VSG in promoting b-cell redifferentiation, implied by
a proportional and transcriptional shift from dedifferentiated to more
mature b-cells.
Using single-molecule fluorescence in situ hybridization (smFISH),
Farack et al. recently reported a unique b-cell subpopulation termed
“extreme” b-cells based on their explicitly high expression of Ins2
and key b-cell function genes with normal to low levels of mature
insulin [75]. Thus, extreme b-cells were attributed a specialized role
in constant basal insulin secretion, which is necessary throughout the
day. Due to the fact that the proportions of extreme b-cells rise in
early T2-diabetic db/db mice, extreme b-cells were speculated to
counteract constant hyperglycaemia present in T2D [75]. Whether
extreme b-cells also play a role in long-term T2D and whether this
subpopulation can be targeted by therapeutic interventions remain
open questions. In our scRNA-seq dataset, we identified an extreme-
like b-cell population in WT and db/db mice based on the smFISH
markers described by Farack and colleagues (Ins2, Ins1, Pcsk1,
Pcsk2, Chga, Chgb, Abcc8 and Kcnj11) (Figure 5B). Although all
markers described by Farack et al. were upregulated in our extreme-
like b-cells, not all markers were as pronounced as reported (e.g.,
Ins1), which is possibly inherent to the different techniques being
used (scRNA-seq versus smFISH). Using single-cell transcriptomics, a
recent study by the Johnson laboratory revealed a b-cell state
exhibiting explicitly high Ins2 that likely reflects the extreme b-cell
state described by Farack and colleagues [68]. Corroborating this, we
found a great overlap of genes enriched in our extreme-like b-cell
population with those reported by the Johnson laboratory (Figure S5,
Supplementary Table 4 and Methods). Surprisingly, we also observed
that the proportion of extreme-like b-cells was lowered in Sham (3%)
and PF (1%) compared to WT (7%) and was restored to WT-level in
VSG (6%, Figure 5C). These findings suggest that, unlike in early-
diabetic compensatory conditions, extreme-like b-cells are lost in
late-stage T2D; however, they can be recovered by VSG intervention.
To better understand the functional relevance of extreme-like b-cells,
we analyzed overexpressed genes in extreme-like b-cells of WT and
db/db mice (Supplementary Table 5). Most genes were common in
extreme-like b-cells of WT and db/db mice, indicating that they share
functional features (Figure S5). GO and KEGG enrichment analyses
revealed terms related to cell respiration, protein processing, ER
stress and protein export ()Figure S5. Extreme-like b-cells of db/db
mice overexpressed insulin processing and secretory genes as well
as genes linked to ER stress and protein synthesis (Figure 5B; Figure
S5), supporting the role of extreme-like b-cells in increasing insulin
secretion. Collectively, our data suggest that the proportion of
extreme-like b-cells changes in number in late-stage diabetes,
eventually contributing to T2D progression. Nevertheless, we show
that the extreme-like state of b-cells can rapidly be regained within
two weeks of VSG intervention and thus might play a role in glycaemic
normalization post-VSG.
2.6. VSG rapidly expands b-cell mass
Loss and dysfunction of b-cells are the primary determinants of
diabetes pathophysiology. Based on the findings from the MMTT,
VSG intervention greatly restores glycaemic control. To understandMOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. This is an open a
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and morphology quantitatively. VSG rapidly triggered a pronounced
expansion of b-cell area within two weeks of intervention, compared
to all other groups (Figure 6A). We reasoned this change to not only
correlate with b-cell redifferentiation, but also expansion of dedif-
ferentiated b-cells. A previous report shows that db/db mice in-
crease b-cell proliferation in the early and intermediate stages of the
disease to compensate for the rising metabolic demand, whereas the
proliferation rate declines in late-stage diabetic db/db mice instead
[28]. Here, we detected a modest, albeit statistically non-significant,
increase in b-cell proliferation in VSG compared to Sham and PF
(Figure 6B and C). Notwithstanding, we cannot rule out the possibility
that the major b-cell proliferative activity occurred during the first
week of VSG, since we labelled the proliferating cells in mice 72 h
before sacrifice. Supporting the proliferative b-cell phenotype, we
identified a cycling b-cell population in our scRNA-seq dataset,
marked by high expression of cell cycle genes (Mki67, Top2a and
Cdk1), which originated from VSG (54/9252, 0.6%) and to a lesser
extent from Sham (14/4491, 0.31%) and PF controls (17/7389,
0.23%, Figure 6D and E). Pathway analysis of VSG-versus PF-
derived b-cells revealed an enrichment of cell cycleerelated terms,
such as positive regulation of cell cycle and negative regulation of
apoptosis (Figure S6). Interestingly, the non-cycling b-cell pop-
ulations of VSG showed a higher expression of Cyclin D2 (Ccnd2), the
essential cell-cycle progression gene in adult b-cells [76], compared
to controls. Additionally, we observed an upregulation of SRY-box
transcription factor 4 (Sox4) and concomitant downregulation of
Cyclin-dependent kinase inhibitor 1 A (Cdkn1a) in non-cycling b-
cells of the VSG group, which has been shown to allow adult b-cell
replication [77] (Figure 6D). These findings suggest that VSG could
trigger a proliferation-competent b-cell state. We next addressed
whether the VSG-derived proliferating b-cell cluster presents a
mature or dedifferentiated identity and found that the proliferating b-
cells from VSG exhibited dedifferentiation features by expressing the
highest levels of Aldh1a3, Cck and Gc. Concomitantly, there was a
lower expression of maturity markers (Ins1, Mafa and Pdx1,
Figure 6F), suggesting that dedifferentiated b-cells are more likely to
enter the cell cycle.
Underscoring the impact of VSG on b-cell mass, we next examined the
uniquely regulated genes that could elucidate the potential proliferative
phenotype in the b-cell population of VSG mice. We found 418 genes
to be upregulated in VSG mice versus control groups (Figure 6G and H),
some of which were related to immune function (Figure 6I). Surpris-
ingly, a number of key genes, remarkably upregulated in VSG, are
documented to be highly expressed during pregnancy, a condition in
which profound adaptive functional and proliferative mechanisms
occur in b-cells. These genes included Sftpd, coding for Surfactant-
associated protein D (SP-D); Carbonic anhydrase 8 (Car8); Tnfrsf11b,
coding for Osteoprotegerin (OPG) and Chgb (Figure 6J). OPG
(Tnfrsf11 b) is a soluble decoy receptor of the TNFR superfamily, best
known to be induced by lactogens and act as a b-cell mitogen by
preventing the interaction of Receptor activator of NF-kB Ligand
(RANKL) and RANK (Figure 6J). OPG robustly activates b-cell prolif-
eration under various conditions, such as pregnancy and young, aged
and diabetic STZ-treated mice [78,79]. Here, we present OPG for the
first time as a possible mediator of b-cell replication in the context of
VSG. In order to further outline the pregnancy-associated genes
induced by VSG, we compared our b-cell dataset with published islet
transcriptome datasets of pregnant mice [80e82] (Figure 6K). We
found 32 common genes induced by both VSG and pregnancy.
Strikingly, these included most key pregnancy genes (Sftpd, Tnfrsf11b,ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 9
Figure 6: VSG rapidly expands b-cell mass. A, Pancreas morphometry analysis reveals that VSG doubled the relative b-cell area (WT, n ¼ 6; Sham, n ¼ 5, PF, n ¼ 3; VSG,
n ¼ 3; WT versus VSG (p < 0.0001); Sham versus VSG (p < 0.0001), PF vs VSG (p ¼ 0.0003)). B, Quantification of b-cell proliferation at study end (WT, n ¼ 6; Sham, n ¼ 5, PF,
n ¼ 3; VSG, n ¼ 3; WT versus VSG (p ¼ 0.019), VSG versus Sham (p > 0.999), VSG versus PF (p ¼ 0.156)). All data are presented as mean  s.e.m and were analyzed by one-
way ANOVA with Bonferroni’s post-hoc test. C, Representative images of immuno-stainings against insulin, glucagon and EdU. Scale is 50 mm D, Dot plot showing expression of
cell cycleerelated genes in cycling and non-cycling b-cells per group. Color intensity shows normalized mean expression in a cell cluster. Expression is scaled per gene. E,
Doughnut plots indicating fraction of proliferating b-cells per group (VSG-54/9252, PF-17/7389, Sham-14/4491). F, Dot plot showing expression of b-cell identity genes in mature,
dedifferentiated and proliferating b-cells of VSG, implying the dedifferentiated signature of proliferating b-cells. Expression is scaled per gene. G, Venn diagram showing uniquely
upregulated b-cell genes in VSG versus control groups. H, Top 10 unique VSG genes (estimated log (FC) > 0.25, B > 150). Log (FC) plotted for VSG versus Sham. IeJ, Matrix plots
showing expression of (i) immune-related and (j) pregnancy-related genes in b-cells per group resolved per subcluster. Color gradient indicates mean z-score scaled gene
expression. K, Upset plot showing the overlap between VSG-specific genes derived from our study and literature curated genes that are differentially expressed in islets during
pregnancy (Layden et al. 2010, Rieck et al. 2009, Kim et al. 2010). Upset plot is used to visualize intersection of sets. The set size bar plot on the left indicates the total number of
genes populating each of our genesets. The intersection size bar plot shows the total number of genes that overlap between two or more sets. The bars highlighted in red refer to
the genes that are uniquely shared among VSG and the participating sets. Limma-trend method was used to find differentially expressed genes for VSG versus Sham and PF at
absolute estimated log (FC) > 0.15 and B > 150. Venn diagrams aided in identifying the VSG-regulated genes.
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Car8 and Socs2), immune-modulatory genes (Il13ra1 and Ifngr2) and
b-cell identity and functionality genes (Mafa, Pdx1, Ins1 and Chgb).
Taken together, we show that VSG increased the b-cell area within
only two weeks and suggest that this increase is attributed to two
additive mechanisms, b-cell redifferentiation and proliferation. More
precisely, our findings indicate that VSG triggers a proliferation-
competent b-cell state characterized by up- and downregulated
expression levels of the cell cycle regulator gene Ccnd2 and the cell
cycle inhibitor gene Cdkn1a, respectively, and induces adaptive
pregnancy-associated factors.
3. DISCUSSION
Bariatric surgeries such as VSG improve glucose control and lead to
high rates of T2D remission in patients [16,83]. Despite the high in-
terest in a global understanding of bariatric surgical mechanisms, with
the overarching objective of finding novel, less-invasive therapeutic
strategies, the exact complement of glucoregulatory mechanisms after
VSG remains elusive.
This study investigates the mechanistic role of VSG in restoring gly-
caemic control after overt T2D, with special regard to b-cell rediffer-
entiation and novel VSG-driving factors in b-cells using single-cell
profiling. In contrast to previous studies, we chose a clinically more-
relevant model of overt late-stage diabetic 16- to 18-week-old db/
db mice. Although the db/db model does not fully recapitulate human
obesity-linked diabetes (amongst other reasons, because it relies on a
rare Lepr mutation and starts very early in life, before b-cell maturation
is fully completed), the db/db model seems to be closer to human b-
cell pathophysiology than DIO models [84]. It mirrors features of
morbid obesity-linked diabetes, representing a common indication for
bariatric surgical interventions, and resembles human T2D b-cell
pathophysiology, including b-cell dedifferentiation. VSG outcomes
were studied 14 days post-surgery to give sufficient time for recovery
but also capture the earliest dynamics where critical metabolic events
would take effect. Clinically, preoperative markers that can predict T2D
remission upon surgery are constantly subject to investigations [85e
88] and raise concerns of the effectiveness of bariatric surgery per-
formed on patients with highly progressed T2D. Strikingly, we
demonstrate that VSG is indeed capable of reversing severe T2D within
only two weeks of intervention, while a mild calorie-restrictive inter-
vention is insufficient to improve T2D in this model. This was reflected
not only on the physiological level, but also the single-cell tran-
scriptome level, as we did not observe relevant differences between
the PF and Sham b-cell transcriptomes. This finding expands our
knowledge of the superiority of VSG over calorie restriction. In contrast
to previous reports showing that calorie restriction is effective in
prediabetes models [20,89], our data indicates that PF becomes
inefficacious in highly progressed T2D.
The only study that addresses the effects of VSG on islet transcriptome
demonstrates a unique regulation by VSG, but could not decipher cell-
type specific contributions [20]. To advance our mechanistic under-
standing of the glycaemic rescue induced by VSG in specific islet cell
types, we conducted a comprehensive single-cell transcriptome
analysis of the islets of Langerhans. Our data revealed that obesity-
driven T2D primarily affected the transcriptome of b-cells and not
that of a-, d- or PP-cells. In particular, Sham-derived b-cells revealed
features of extreme dedifferentiation and compromised b-cell identity
and function. Likewise, we demonstrate that b-cells majorly benefitted
while a-, d- and PP-cells only benefitted to a low extent from surgicalMOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. This is an open a
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rescue by VSG in our model. Furthermore, we suggest that the intrinsic
molecular changes in b-cells, to an extent, account for the marked
glucoregulatory improvements after VSG intervention. However, we
cannot rule out the possibilities that the transcriptional changes reflect
secondary outcomes of preceding peripheral metabolic improvements
driven by VSG, or that the limited number of VSG-treated mice used for
metabolic assessment and scRNA-seq falsely captured physiological
outliers. Additionally, our conclusions on b-cell function were made
based on transcriptomic data and MMTTs assessing the systemic
regulation of glycaemia, including gastro-intestinal functions, instead
of pure b-cell function.
Given the remarkable increase in insulin secretion after VSG, possibly
driven by extrinsic signals such as GLP-1 and adaptations inherent to
b-cells, we reasoned that there must be intrinsic compensatory
mechanisms in VSG-derived b-cells that ensure proper insulin syn-
thesis, processing and secretion. Indeed, our data revealed uniquely
upregulated levels of insulin secretion and processing machinery as
well as UPR, which likely mirrors the parallelly increased ER stress and
insulin secretion levels present in VSG. Furthermore, our findings put
forward ERAD to mitigate ER stress and maintain b-cell homeostasis in
VSG-treated mice.
Talchai et al. [4] demonstrated that the loss of functional b-cells in T2D
mainly emerges due to b-cell dedifferentiation and correlates with the
increased expression of Aldh1a3 and decreased levels of mature b-cell
markers. In fact, a few studies address b-cell dedifferentiation or
maturation markers after bariatric surgery. It was shown that two
forms of bariatric surgery, Roux-en-Y gastric bypass (RYGB) and VSG,
reduce b-cell dedifferentiation in diabetic Goto-Kakizaki (GK) rats [90]
or improve b-cell identity markers in young (4 weeks and 8e10 weeks
old) diabetic db/db mice [21,26]. However, a complete single-cell
mRNA profile of the changes occurring on the b-cell level to dissect
the cellular and molecular changes occurring during surgical inter-
vention and the resulting physiological phenotyping remained elusive.
VSG triggered fast b-cell recovery to a more functional state, char-
acterized by improved expression profiles of b-cell identity and func-
tionality markers as well as a remarkable decline in dedifferentiation
markers. Furthermore, we identified a route of redifferentiation, evi-
denced by unique cell transitions from the dedifferentiated to a more
mature b-cell state using RNA velocity as well as by a higher pro-
portion of mature and lower number of dedifferentiated b-cells. Of
note, the b-cell maturity marker Ucn3 did not recover after VSG in our
late-stage T2D db/db mice (16e18 weeks). Differences in UCN3 levels
likely depend on the stage of T2D as shown in a study by the Ben-Zvi
laboratory [21], in which VSG progressively improved UCN3 levels
between one week and one month after VSG in early diabetic (8e10
weeks) db/db mice. Nevertheless, our data shows that even in the
absence of Ucn3, b-cells recover within two weeks of VSG interven-
tion, which is in line with a study revealing that UCN3 is functionally not
required in b-cells [91]. Furthermore, based on the findings by the
Ben-Zvi laboratory [21], we speculate that VSG would likely further
enhance b-cell redifferentiation on a longeterm scale. It has been
reported that Gastrin expression is turned on in a subset of b-cells after
severe hyperglycaemia [42]. Interestingly, lowering of glycaemia post-
VSG decreased the expression of Gast and Cck, indicating that
hyperglycaemia drastically compromises the b-cell identity.
Reports on b-cell mass after bariatric surgery are highly inconsistent.
Two studies show an increase in b-cell mass upon VSG in GK rats [92]
and upon RYGB in pigs [93], whereas others report no change in b-cellccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 11
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mice [21] and decreased b-cell area in DIO mice [95] upon VSG. In our
model of late-stage T2D, we show that VSG increased b-cell area and
that this expansion is most likely driven by additive mechanisms of b-
cell redifferentiation and proliferation. We found that VSG induces a
proliferation-competent b-cell state by unique changes in cell-cycle
regulator genes and, surprisingly, an induction of pregnancy-
associated factors. Maternal b-cells compensate for physiological in-
sulin resistance by proliferating and expanding during pregnancy to
maintain maternal euglycaemia [96]. These adaptations have been re-
ported to be mainly driven by increased levels of prolactin and placental
lactogens [97e99] and proven to be distinct from those activated by
nutritional and injury stress [80,100]. A study reported that male islets
can also acquire a pregnancy-like signature through exposure to pro-
lactin [101]. Indeed, a possible link was provided by a recent study
showing that VSG increased blood prolactin levels in male patients [102].
Future research will need to validate this observation and investigate the
mechanistic link between VSG and prolactin-levels as well as the exact
downstream consequences on b-cells in a setting of VSG. The role of the
commonly upregulated genes in b-cells during pregnancy and upon
VSG, including Sftpd, Car8 and Tnfrsf11b (OPG), is largely unknown but
may be causally linked to compensatory b-cell function and proliferation,
both of which are well-known phenomena during pregnancy
[80,82,103]. Sftpd has been shown to be overexpressed in newly
formed b-cells during the perinatal period and during pregnancy, and
has been suggested to confer anti-inflammatory properties to b-cells
[81,104]. Car8 expression in adult b-cells was found to be weak,
although it is upregulated in mice during pregnancy [82,101]. In
contrast, OPG is well known for its mitogenic effects in b-cells under
various settings, including during pregnancy and when pharmaceutically
administered [78,105e107]. In this study, we present OPG as a po-
tential new b-cell mitogen induced by VSG that could contribute to b-cell
expansion and thus to the restoration of glycaemia after VSG. Cytokines
present after VSG or increased prolactin levels might be upstream
drivers, inducing OPG expression upon VSG [78,106,107]; however, this
needs to be conclusively proven in future experiments. Taken together,
we provide evidence for the superiority of VSG in a clinically-relevant,
morbidly obeseeT2D mouse model and give insights into the diverse
b-cell mechanisms that underlie VSG-mediated T2D remission. Addi-
tionally, this understanding serves as a basis for the potential discovery
of novel therapeutic targets, including pregnancy pathways, that might
be able to mimic bariatric surgery for T2D therapy.
4. METHODS
4.1. Animals
Male Lepr-deficient mice, homozygous for Lepr-db (db/db mice), and
corresponding control mice, WT for Lepr (both stock #000642,
BKSCg-Dock7mþ/þLeprdb/J), were purchased from The Jackson
Laboratory (Maine, US) and maintained under standard controlled
conditions. Db/db mice were single-housed one week prior to sur-
gery. WT mice were housed in groups of 2e4 per cage. Before
surgery, mice were matched for body weight and metabolic pa-
rameters and assigned to VSG, Sham and pair-fed (PF) groups for
surgery at the age of 16e18 weeks. All animal experiments were
carried out in compliance with the German Animal Protection Act and
with the approved guidelines of the Society of Laboratory Animals
(GV-SOLAS) and the Federation of Laboratory Animal Science Asso-
ciations (FELASA). This study was approved by the Animal Use and
Care Committee of Bavaria, Germany.12 MOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. T4.2. Surgical procedures
VSG and sham surgeries were conducted as described previously
[108] (PMID: 23554454). Briefly, VSG surgery included the lateral
excision of 70% of the stomach, leaving a tubular gastric remnant in
continuity with the esophagus superiorly and the pyloric sphincter and
duodenum inferiorly. For VSG sham surgery (Sham), the stomach was
isolated, followed by manual application of pressure with blunt forceps
at a vertical line, starting at the esophagus superiorly and ending at the
duodenum inferiorly. Surgeries were performed on 12-h fasted mice
after administration of Buprenorphin (0.1 mg/kg body weight) and
isoflurane anaesthesia. WT mice were considered a healthy control
group and did not undergo surgery.
4.3. Postoperative care and dietary regimen
Postoperatively, all surgical groups received subcutaneous injections
of Meloxicam (1 mg/kg body weight daily for 2e3 days) and warm
saline (1 mL daily for 2e3 days). Mice had access to ad libitum
Osmolite HiCal liquid diet (Abbott) for 3 days after surgery before
being returned to a solid diet on day 4. Henceforth, VSG and Sham
mice received ad libitum chow. A subgroup of Sham mice was pair-
fed to match the food intake of VSG mice. To this end, PF mice
received pre-weighed amounts of chow once daily, calculated based
on the mean food consumption by the VSG group during the previous
24 h.
4.4. Mixed meal tolerance test
Mixed-meal tolerance tests (MMTTs) were performed 14 days prior to
and 13 days post-surgery. Mice were fasted for 6 h and tail vein blood
was collected for basal blood glucose and insulin measurements.
Subsequently, mice were gavaged with 200 mL of Osmolite HiCal liquid
diet enriched with 20% dextrose. Tail vein blood was collected after
15, 30, 60, and 120 min to assess glucose and circulating insulin
levels during the MMTT. Blood glucose was quantified in plasma using
mouse glucose assay kit (CrystalChem, #81692). Levels of circulating
insulin were assayed in plasma using mouse-specific ELISA kits
(CrystalChem, #90080).
4.5. HOMA insulin resistance (HOMA-IR) index
The HOMA-IR index was calculated by multiplying fasting blood
glucose (mg/dL) with fasting plasma insulin (mIU/mL) and dividing by
405.
4.6. Proliferative cell labeling in mice
To label proliferative cells, mice were injected with 10 mg/g body
weight 5-ethynyl-20-deoxyuridine (EdU, Thermo, #E10187) intra-
peritoneally once a day for 3 consecutive days before the end of
experiment.
4.7. Islet isolation and single cell preparation
Pancreata were excised and digested using collagenase P (Roche,
#11213857001) followed by centrifugation using OptiPrep density
gradient medium (Sigma, #D1556). Isolated islets were handpicked
under a stereomicroscope and cultured in RPMI 1640 medium (Invi-
trogen, #21875091) supplemented with 10% FCS (GIBCO) and 1%
penicillin-streptomycin (Life Technologies, #15140122) for 1 h at
37 C. For single cell suspension, islets of different sizes were
dissociated by incubation with TrypLE (Life technologies, #12605) for
12e15 min at 37 C and gentle repeated pipetting. Cells were washed
twice with FACS buffer (2% FCS in PBS) before continuing with library
generation for single-cell RNA sequencing.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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4.8. Single-cell RNA sequencing: RNA preparation, library
generation and sequencing
Single-cell samples from islets derived from WT (n¼ 2), Sham (n¼ 2),
PF (n ¼ 1) and VSG mice (n ¼ 2) were prepared as described above.
Number of dead cells was estimated by trypan blue staining. Single-
cell libraries were generated using the Chromium Single Cell 30
GEM, Library & Gel Bead Kit v3 (10x Genomics, #1000075) according
to the manufacturer’s instructions. Briefly, to obtain a target cell
number of 10,000 cells per sample, approximately 16,000 cells per
sample were loaded onto a single channel of the 10x chip to generate
Gel Bead-in-Emulsions (GEMs). These underwent reverse transcription
to barcode RNA before cleanup and cDNA amplification. Afterwards,
enzymatic fragmentation and attachment of the 50 adaptor and sample
index was performed. Libraries were sequenced on a NovaSeq6000
(Illumina) with 150 bp paired-end sequencing.
4.9. Immunohistochemistry and EdU assay
Pancreata were fixed in 4% (w/v) neutrally buffered formalin and
entirely cross-sectioned into 3e5 parallel, equidistant slices per case.
Maintaining their orientation, the tissue slices were vertically
embedded in paraffin to ensure complete coverage of the entire
pancreas, including head, neck, body and tail. Sections of 3-mm
thickness were cut. The following primary antibodies were used:
Monoclonal rabbit anti-insulin, #3014, Cell Signaling, 1:400; Polyclonal
guinea pig anti-insulin, PA1-26938, Thermo Scientific, 1:200, Poly-
clonal guinea pig anti-glucagon, M182, Takara, 1:2500; Monoclonal
mouse anti-GRP78, BD Bioscience, 610,979, 1:200; Polyclonal goat
anti-Sel1L, Novus Biologicals, NB100-93463, 1:200; Polyclonal rabbit
anti-MafA N-terminal region, ARP47760_P050, Aviva systems biology,
1:200; polyclonal rabbit anti-UCN3, H-019-29, Phoenix Pharmaceuti-
cals, 1:500; Polyclonal goat anti-Slc2a2, ab111117, abcam, 1:300;
Polyclonal rabbit anti-Aldh1a3, LS-C498339-100, LSBio, 1:300;
Polyclonal rabbit anti-Slc5a10, ab167156, abcam, 1:300 and Mono-
clonal mouse anti-Pcsk1, sc-100578, Santa Cruz, 1:200. The following
secondary antibodies were used: AlexaFluor750-conjugated goat anti-
rabbit, A21039, Invitrogen, 1:2500; Donkey anti-rabbit IgG 488, Invi-
trogen, A21206, 1:800; Donkey anti-rabbit IgG 555, Invitrogen,
A31572, 1:800; Biotinylated goat anti-guinea pig, BA7000, Vector,
1:100; Cy3-conjugated streptavidin, SA1010, Invitrogen 1:100;
Donkey anti-guinea pig Alexa 488, 706-545-148, Dianova, 1:800;
Donkey anti-mouse IgG 555, Invitrogen, A31570, 1:800 and Donkey
anti-goat IgG 555, Invitrogen, A21432, 1:800. EdU staining was per-
formed as per manufacturer’s protocol (Click-IT EdU Alexa Fluor 647
Imaging Kit, Thermo Fisher Scientific). Nuclei were labelled with
Hoechst33342 (H1399, Thermo Fischer) or 40,6-diamidino-2-
phenylindole (DAPI; Life Technologies, 1:500). Slides were mounted
with VectaShield and imaged using confocal microscopy (Zeiss LSM
Airy Scan).
4.10. Pancreas morphometry and quantification
For pancreas quantification, 6 tissue sections per animal were
analyzed. The stained tissue sections were scanned with an Axi-
oScan.Z1 digital slide scanner (Zeiss, Jena, Germany) equipped with a
40 magnification objective. Subsequently, islets were automatically
detected (100 islets on average per animal) and insulin-, glucagon-
and EdU-positive cells were quantified using the image analysis
software Definiens Developer XD2 (Definiens AG, Germany). To eval-
uate a- and b-cell replication, the respective ratio of glucagon/EdU/
Hoechst or insulin/EdU/Hoechst co-positive cells to the total glucagon-
or insulin-positive cells were quantified.MOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. This is an open a
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The results are expressed as mean  s.e.m. (Standard Error Mean).
For statistical comparison of longitudinal data, two-way ANOVA cor-
rected by Bonferroni’s multiple comparison test was used. Any other
data were compared by one-way ANOVA corrected by Bonferroni’s
multiple comparison test or student’s t-test. A value of p<0.05% was
considered statistically significant. Analyses were performed using
GraphPad Prism 9 Software (GraphPad Software, USA).
4.12. Preprocessing of 10x scRNA-seq data
The CellRanger analysis pipeline (v3.1.0) provided by 10x Genomics
was used for demultiplexing the binary base call (BCL) files, aligning
reads to the mm10 genome build and reading filtering, barcode and
unique molecular identifier (UMI) counting to generate a digital gene
expression matrix (DGE). The standard cell detection algorithm of
CellRanger was used to select high quality barcodes based on the
overall distribution of total UMI counts per cell. All downstream ana-
lyses, unless stated otherwise, were performed on Python 3.7.7 using
the Scanpy package [109] (v1.4.6). Next, the cell-by-gene count
matrices for each sample were iteratively concatenated into one merged
dataset. Standard preprocessing and quality control (QC) measures
were adopted to filter noisy and unreliable cells and genes from the raw
data obtained after sequencing. These included filtering cells based on
number of detected genes, count depth and fraction of counts origi-
nating from mitochondrial genes, which is indicative of potential cellular
stress. This ensured that downstream analysis results were obtained
only with viable cells and not technical artifacts, apoptotic cells, dou-
blets, etc. On the basis of the joint distribution of these QC metrics, we
investigated cells for anomalous behavior, followed by filtering using
thresholding decisions. Briefly, genes expressed in fewer than 10 cells
were excluded. Additionally, low-quality cells were removed if they 1)
showed a high fraction (>20%) of counts due to mitochondrial tran-
scripts, 2) expressed more than 7,000 genes, 3) had more than
100,000 UMI counts and 4) expressed fewer than 500 genes (the
argument being that below this threshold, potentially dying cells or
empty droplets contaminated by ambient RNA expression would be
picked up for analysis). Five non-endocrine clusters, identified using
bona fide markers, including ductal cells (expressing Krt19), acinar cells
(expressing Prss2), endothelial cells (expressing Plvap), stellate cells
(expressing Col1a2) and immune cells (expressing Cd74), were
removed from further analysis. Furthermore, we applied Scrublet
pipeline [110] (v0.2.1, with manually adjusted parameters, see Code) to
mark potential technical artifacts of cell doublets that can arise due to
arbitrary co-encapsulation of two cells with differing expressions. Pre-
dicted doublet-like cells that co-localized in distinct clusters and co-
expressed endocrine and non-endocrine markers were not consid-
ered for analysis. Examining the distribution of cell counts and genes
and thresholding on outlier peaks, we measured 19,878 endocrine cells
from WT and Sham with a median number of transcripts per cell of
approximately 3962 and a mean of 33,206 counts per cell. Additionally,
we detected 35,941 endocrine cells from Sham, PF and VSG collectively
and detected a median number of transcripts per cell of approximately
3621 and a mean of 30,251 counts per cell. Cell filtering was followed
by normalization of the read counts using the scaling normalization
function computeSumFactors (with min.mean¼ 1) from scran available
through R. This was done to account for cell-specific biases due to
differences in sequencing depth and capture efficiency between cells
and the values that were subsequently log-transformed. Additionally,
highly variable genes (HVGs) to be used as input for dimensionality
reduction were identified using function pp.highly_variable_genes fromccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 13
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in principal component analysis (PCA), followed by clustering and
visualization via UMAP.
4.13. Dimensionality reduction, clustering and cell-type annotation
The single-cell RNA-seq data was analyzed for transcriptomic simi-
larities between cells in two-dimensional embedding by computing a
k-nearest-neighborhood (KNN) graph using the function pp.neighbors
from Scanpy. Prior to this, 50 principal components were computed
with principal component analysis (PCA) on the list of 4000 highly
variable genes using the function pp.pca. The size of the local
neighborhood for the KNN graph was set to 30 and the top 30 prin-
cipal components were used. This was followed by computation of a
Uniform Manifold Approximation and Projection (UMAP) embedding
(v0.4.0) and Louvain-based clustering (louvain: v0.6.1, igraph: v0.8.0)
using Scanpy functions tl.umap and tl.louvain, respectively. Important
to note here is that no fixed resolution parameter was used; instead,
Louvain clustering was repeated at different resolutions within sub-
clusters to account for specific differences in the data manifold.
Additionally, each UMAP visualization in the study was plotted after re-
computing the KNN graph and UMAP on the cell subset under study
using the first 30 principal components and the highly variable genes
as initially determined. Significant endocrine clusters were identified
on the basis of mRNA expression of well-known canonical markers,
mainly, Ins1, Gcg, Sst and Ppy. We also identified cells expressing a
combination of hormones that could be indicative of polyhormonal
cells or potential doublets. As studying cells expressing multiple
hormones was beyond the scope of the current study, we did not
further resolve the identification of polyhormonal singlets from
doublet-like islet clusters. For the identification of b-cell sub-
populations, we computed a new KNN graph followed by Louvain
clustering at varied resolutions using a combination of literature-
based gene sets, as well as enriched gene ontologies and path-
ways using the web interface EnrichR [111]. The gene expression
profile of each cluster was compared to the profiles of all other cells
using a variance-overestimated t-test, implemented through Scanpy
using tl.rank_genes_groups, in order to identify key marker genes for
each cluster that additionally assisted in annotating the more un-
conventional and transient b-cellestates.
4.14. Differential expression analyses between treatment
interventions and subpopulations
In order to explore the divergent transcriptional programs in b-cells
accompanying VSG, differentially expressed genes were determined in
our dataset by the comparison of b-cells between treatment groups
and control viz. WT, Sham, PF and VSG. Moreover, b-cell subclusters
were also described in more detail by exploring VSG-specific effects.
For this purpose, differential analysis tests were performed on the log-
normalized counts (output from scran method, which accounts for li-
brary size differences) using limma-trend from R package limma [112]
(v3.42.2) and edgeR [113] (v3.28.1) through an rpy2 (v3.2.7) interface.
Additionally, to exclude spurious results, genes expressed in fewer
than 1% cells in either of the two groups tested were also removed.
Genes with a false discovery rate (FDR) < 0.01 were used for sub-
sequent analysis unless stated otherwise. Briefly, a design matrix was
constructed with cell type and batch information. Using the lmFit
function, linear models were fit to the expression of each gene. The
genes were subsequently ranked with enhanced statistical power14 MOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. Tusing an empirical Bayes method, eBayes, to detect significant
changes in expression. Finally, the top-ranked genes were corrected
for multiple testing and FDR using the adjustment method (Benjamini-
Hochberg or BH) and extracted from the linear model fit. Gene set
enrichment analysis was subsequently performed using the web-
based tool EnrichR [111] (https://maayanlab.cloud/Enrichr/), which
uses a standard hypergeometric test or Fisher’s exact test to report
enrichment results, and significantly regulated KEGG pathways and GO
terms/ontologies were reported. The results were visualized using
custom plotting functions.
4.15. Inferring pseudotime, cluster connectivity and cell transitions
In order to assess transcriptomic similarity of b-cells between
treatment groups, we applied Partition-based graph abstraction
(PAGA) to the KNN-graph using the Scanpy function tl.paga, including
low-connectivity edges. PAGA is a measure of cluster connectivity
wherein edge weights indicate significance of a connection.
To infer pseudotime of b-cell dedifferentiation upon treatment, we
ordered cells along a trajectory using a random-walk based distance
metric, employing diffusion pseudotime (DPT) computed with tl.dpt in
Scanpy. For this purpose, we randomly assigned a root cell within the
dedifferentiated b-cells and followed the direction cells transitioned
from after this starting point. Prior to this step, all b-cells were batch-
corrected using BBKNN [114] (v1.4.1) from the Scanpy external
package (using external.pp.bbknn with default settings) in order to
augment pseudotime inference by minimizing the variation added by
the different sample batches. This resulted in a modified neighborhood
graph that could be directly used to infer the maturation trajectory
using DPT. b-cells were grouped according to Sham, VSG and WT and
visualized by reconstruction of expression changes in genes that were
robustly and gradually regulated along this one-dimensional axis.
Extreme-like b-cells were excluded from this analysis, as they were
not part of the linear trajectory and formed a separate cluster by
expressing few very specific genes.
In order to identify direction of potential cell movements upon VSG
treatment, we applied RNA velocity to our single-cell data using the
default stochastic model as implemented in the scVelo python
package (v0.2.2). Model fitting and subsequent velocity estimation
was performed in VSG-treated and Sham control b-cells. The data
was prepared following standard protocol and using default param-
eters. Briefly, 2000 top genes were retained after filtering genes that
did not pass a minimum threshold of 20 counts simultaneously for
spliced and unspliced mRNA. This was followed by computing the
first and second order moments for each cell using 30 principal
components with the 30 nearest neighbors. Two additional metrics,
namely velocity confidence and velocity length, were also estimated,
as our key focus was to affirm the extent to which VSG improved re-
differentiation (Supplementary Table 4). The length was indicative of
the pace at which differentiation occurs; thereby, higher values
suggested faster transition. Confidence, on the other hand, was a
measure of correlation within the velocity vector fields, with higher
values indicating higher coherence.
4.16. Scoring single-cell identity with ERAD and UPR markers
In order to assign to each cell ERAD and UPR scores, we extracted from
literature several genes that have been implicated in ERAD and UPR
and serve as markers for the two critical quality-control machineries
within a cell (Supplementary Table 2). Scores were then computedhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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using the tl.score_genes function in Scanpy (with default settings) for
each of the groups (WT, Sham, PF and VSG) using curated ERAD and
UPR gene signatures. Statistical differences of the cell scores among
the four groups were further assessed using Welch’s Heteroscedastic F
Test, which does not assume variance homogeneity like ANOVA, and
using Bonferroni’s correction to adjust the significance level for pair-
wise comparisons (p value < 0.01, welch.test from R package one-
waytests (v2.4)).
4.17. Comparison of b-cell extreme markers to those published by
Modi et al., 2019 and Farack et al., 2019
To compare our extreme-like b-cells to the extreme b-cells previously
described in literature, we referred to a publicly available single-cell
RNA sequencing study by Modi et al. [68], who characterized
Ins2(GFP)high b-cells as synonymous to the extreme b-cells reported by
Farack et al. [75]. Briefly, genes that were differentially expressed along
the GFP gradient were indicated as specific markers distinguishing
extreme b-cells from the rest and were subsequently used as a
signature for our study (Supplementary Table 3). Differentially
expressed genes between extreme-like vs noneextreme-like b-cells in
WT and, additionally, across all db/db cells collectively (Sham, PF and
VSG-derived b-cells) were used for the comparison. Differential
expression analysis was performed using limma-trend from R package
limma (v 3.42.2) and edgeR (v3.28.1) through an rpy2 (v3.2.7) inter-
face. Genes that were expressed in fewer than 1% cells in either of the
two groups tested were removed, and genes with a false discovery rate
(FDR) < 0.01, B > 50 and an absolute estimated log(fold
change)> 0.2 were used as input. The B scores represent the log-odds
that a gene is significantly differentially expressed. Following this, Venn
diagrams were plotted to reveal the intersection between extreme-like
b-cells identified in this study with those from Modi et al.
4.18. Comparison between VSG-specific b-cell markers and
literature curated differentially expressed genes in pancreatic islets
during pregnancy
To assess similarities between VSG- and pregnancy-specific b-cell
adaptations, we compared published islet transcriptome datasets
from pregnant versus non-pregnant mice [80e82] with our VSG
dataset. To obtain genes unique to VSG, we compared genes from
all groups versus control groups (Sham and PF, respectively) using
limma-trend as mentioned above, thresholded with an absolute
estimated log(fold change) > 0.15 and B > 150. We used Venn
diagrams to identify the VSG-unique intersection, including the
overlapping VSG/WT intersection (representing genes with expres-
sion levels restored to WT) for up- and downregulated genes
separately. The list of genes obtained from this analysis was sub-
sequently compared to differentially expressed genes in islets
during pregnancy, derived from Rieck et al., Layden et al. and Kim
et al. The intersection was then visualized using an upset plot. The
set size bar plot indicates the total number of genes in each set,
while the intersection size bar plot shows the total number of genes
that overlap between two or more sets.
4.19. Data and code availability
The single-cell RNA sequencing dataset generated in this study has
been deposited at the National Center for Biotechnology Informa-
tion Gene Expression Omnibus (GEO) under accession number
GSE174194, along with the code and custom scripts for analyzing
scRNA-seq data generated in this study which is available at
GitHub (https://github.com/theislab/2021_Oppenlaender_Palit_
Pancreas_VSG).MOLECULAR METABOLISM 54 (2021) 101330  2021 The Authors. Published by Elsevier GmbH. This is an open a
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